Kenneth Beer is a Dermatology physician affiliated with University of Miami. OpenAlex indexes 149 publications with 2,629 citations (h-index 29); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 N Dixie Hwy
Suite 305
West Palm Beach, FL 334012712
Telephone
561-600-4848Provider last certified this registry record 22 Mar 2021.
Clinical trials
- Kybella for the Treatment of Flank Fat (FF)
Sponsor: Beer, Kenneth R., M.D., PA
- Juvederm Voluma® XC for the Treatment of Hypoplastic Chin
Sponsor: Kenneth Beer
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202522 payments
- REVANCE THERAPEUTICS, INC.Program year20252 payments
- Galderma Laboratories, L.P.Program year202515 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
32.4%RNA Synthetase Inhibitor Antibacterial18.6%Mupirocin100%Part D≥56 patientsCorticosteroid13.8%Mometasone Furoate100%Part D≥50 patientsSensory organs
28.2%Corticosteroid21%Clobetasol Propionate100%Part D≥47 patientsAminoglycoside Antibacterial4.2%Gentamicin Sulfate100%Part D<11 patients+ 1 more class in this area
Anti-infectives
19.9%Azole Antifungal7.2%Ketoconazole100%Part D≥18 patientsFirst-generation cephalosporins5.7%Cephalexin100%Part D≥24 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safe and Effective Chin Augmentation With the Hyaluronic Acid Injectable Filler, VYC-20L
Dermatologic Surgery
2020 - ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat: Results From a 12-Month Open-Label Study
PubMed
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Carlos Singer
University of Miami
Kara Cavuoto, MD
University of Miami
Sixto Arias, MD
University of Miami
Richard Kardon, DO
University of Miami
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”